Updated:
Juno Therapeutics
Juno Therapeutics is a clinical-stage biotechnology company based in Seattle, United States, founded in 2013. It develops immunotherapies for cancer treatment.
Juno Therapeutics
Juno Therapeutics is a clinical-stage biotechnology company based in Seattle, United States, founded in 2013. It develops immunotherapies for cancer treatment. The company has secured $310 million in total funding.
General information
Firm type
Asset Manager
Year founded
2013
Location
Region
North America
Country
United States
City
Seattle
Corporate office
Seattle, WA, United States
Principals
Hans Bishop
Chief Executive Officer (co-founder)
Larry Corey
Co-founder
Cary Pfeffer
Co-founder
Mark J. Litton
Co-founder
Sector focus
Frequently asked questions
Who ran investment decisions at Juno Therapeutics?
Hans Bishop served as CEO from founding in 2013 through the acquisition. The venture investors, including Arch Venture Partners and Flagship Ventures, held board seats and influenced strategic funding decisions (per SEC filings, 2014).
What investment stages did Juno typically target?
Juno targeted drug development from preclinical research through Phase 2 clinical trials. It did not act as an investor but as a biotech firm conducting clinical-stage work (per FDA clinical trial registries).
Which sectors did Juno avoid?
Juno focused exclusively on oncology cell therapies and did not materially engage in other therapeutic areas, medical devices, or diagnostics (per clinical trial data).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: